secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ayala Pharmaceuticals, Inc. (—)
CIK:        0001100397
Form:       8-K
Filed at:   2023-10-20T23:59:59+00:00
Accession:  0001493152-23-037852
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.01, 3.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ayala Pharmaceuticals closes merger with Biosight, adds AML drug aspacytarabine
-------------------------------------------------------------------------------

- Merger completed Oct 18, 2023; ~5.9M Ayala shares issued to former Biosight holders at 1.82285 exchange ratio.
- Pipeline expands: adds aspacytarabine (BST-236) for AML; Phase 3 AL102 for desmoid tumors continues.
- Roy Golan appointed CFO, replacing interim CFO Igor Gitelman, effective at closing.
- Board changes: Dr. Samir Khleif resigned; new directors Yuval Cabilly, Pini Orbach, Bridget Martell appointed.
- Combined company continues on OTCQX under ticker ADXS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1100397/000149315223037852/0001493152-23-037852-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1100397/000149315223037852/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-037852

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer